These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 30564580)
41. Discovery of a heparan sulfate 3-O-sulfation specific peeling reaction. Huang Y; Mao Y; Zong C; Lin C; Boons GJ; Zaia J Anal Chem; 2015 Jan; 87(1):592-600. PubMed ID: 25486437 [TBL] [Abstract][Full Text] [Related]
42. Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity. Yoneda A; Asada M; Oda Y; Suzuki M; Imamura T Nat Biotechnol; 2000 Jun; 18(6):641-4. PubMed ID: 10835602 [TBL] [Abstract][Full Text] [Related]
43. Glucuronyl C5-epimerase an enzyme converting glucuronic acid to iduronic acid in heparan sulfate/heparin biosynthesis. Li JP Prog Mol Biol Transl Sci; 2010; 93():59-78. PubMed ID: 20807641 [TBL] [Abstract][Full Text] [Related]
44. Heparosan-derived heparan sulfate/heparin-like compounds: one kind of potential therapeutic agents. Li P; Sheng J; Liu Y; Li J; Liu J; Wang F Med Res Rev; 2013 May; 33(3):665-92. PubMed ID: 22495734 [TBL] [Abstract][Full Text] [Related]
46. Real-Time Study of the Specific Interactions of Lactoferrin with Mimicked Heparan Sulfate Meshes Using Ordered Porous Layer Interferometry. Zhang Y; Ma N; Wang L; Liu L; Wang T; Liu H; Qian W Anal Chem; 2024 Jul; ():. PubMed ID: 38989558 [TBL] [Abstract][Full Text] [Related]
47. Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Krauel K; Preuße P; Warkentin TE; Trabhardt C; Brandt S; Jensch I; Mandelkow M; Hammer E; Hammerschmidt S; Greinacher A Blood; 2019 Feb; 133(9):978-989. PubMed ID: 30573633 [TBL] [Abstract][Full Text] [Related]
52. Complete biosynthesis of a sulfated chondroitin in Escherichia coli. Badri A; Williams A; Awofiranye A; Datta P; Xia K; He W; Fraser K; Dordick JS; Linhardt RJ; Koffas MAG Nat Commun; 2021 Mar; 12(1):1389. PubMed ID: 33654100 [TBL] [Abstract][Full Text] [Related]
53. Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection. Magnani HN Clin Appl Thromb Hemost; 2021; 27():1076029620977702. PubMed ID: 33539214 [TBL] [Abstract][Full Text] [Related]
54. Understanding the mechanisms that facilitate specificity, not redundancy, of chemokine-mediated leukocyte recruitment. Dyer DP Immunology; 2020 Aug; 160(4):336-344. PubMed ID: 32285441 [TBL] [Abstract][Full Text] [Related]
55. Porcine Mucosal Heparin Shortage Crisis! What Are the Options? Fareed J; Jeske W; Ramacciotti E Clin Appl Thromb Hemost; 2019; 25():1076029619878786. PubMed ID: 31559856 [No Abstract] [Full Text] [Related]
56. Recombinant Heparin-New Opportunities. Glass CA Front Med (Lausanne); 2018; 5():341. PubMed ID: 30564580 [TBL] [Abstract][Full Text] [Related]
57. Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Peterson S; Frick A; Liu J Nat Prod Rep; 2009 May; 26(5):610-27. PubMed ID: 19387498 [TBL] [Abstract][Full Text] [Related]
58. Metabolic engineering of mammalian cells to produce heparan sulfates. Thacker BE; Sharfstein ST Emerg Top Life Sci; 2018 Oct; 2(3):443-452. PubMed ID: 33525792 [TBL] [Abstract][Full Text] [Related]
59. Antibody-based assay for N-deacetylase activity of heparan sulfate/heparin N-deacetylase/N-sulfotransferase (NDST): novel characteristics of NDST-1 and -2. van den Born J; Pikas DS; Pisa BJ; Eriksson I; Kjellen L; Berden JH Glycobiology; 2003 Jan; 13(1):1-10. PubMed ID: 12634318 [TBL] [Abstract][Full Text] [Related]